Table 1.
Multiple endocrine neoplasia type 1 (MEN1) mouse models and their main phenotypic features
| Model | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|---|---|---|---|---|---|---|---|---|---|
| Typea | Cv | Cv | Cv | Cn | Cn | Cn | Cn | Cv | Cv |
| Men1 exons deleted | 2–4 | 3–8 | 3 | 3–8 | 3 | 3–8 | 2 | 2 | 1–2 |
| Replacement cassetteb | PGK-Neo | PGK-Neo | Neo-TK | PGK-Neo/Rip-Cre | PGK-Neo/Rip-Cre | PGK-Neo/Pth-Cre | PGK-Neo/Rip-Cre | PGK-Neo | PGK-Neo |
| Strainc | − | Mixed NIH Black Swiss/129 | 129 | Mixed C57/FVB/129 | Mixed C57/129 | Mixed FVB/129 | Mixed C57/129 | Mixed C57/129 | Mixed C57/129 |
| Outcome | Embryonic lethality | Viable | Viable | Viable | Viable | Viable | Viable | Viable | Viable |
| Tumour developmentd | |||||||||
| Parathyroid | − | + | + | − | − | + (↑Ca) | − | + | + (↑Ca) |
| Pancreas | − | + (INS) | + (INS, GLU) | + (INS) | + (INS) | − | + (INS) | + (INS, GLU) | + (INS, GLU, SSTR2, CgA) |
| Pituitary | − | + (PRL) | + (PRL, GH) | − | − | − | + (PRL) | + (PRL, NF) | + (PRL, GH, ACTH, SSTR2, CgA) |
| Adrenal cortex | − | + | + | − | − | − | − | + | +(3β-HSD), ↑Cort |
| Phaeochromocytoma | − | + | − | − | − | − | − | + | + (TH) |
| Gastric NET | − | + | − | − | − | − | − | − | − |
| Thyroid | − | + | + | − | − | − | − | + | + |
| Testicular | − | − | + (LD) | − | − | − | − | + (LD) | + (LD) |
| Extra pancreatic gastrinoma | − | − | + | − | − | − | − | − | − |
| Ovarian | − | − | + (SC) | − | − | − | − | + (SC) | + (SC) |
| Year published | 2001 | 2001 | 2003 | 2003 | 2003 | 2003 | 2004 | 2007 | 2009 |
| References | Scacheri et al. (2001) | Crabtree et al. (2001) | Bertolino et al. (2003a) | Crabtree et al. (2003) | Bertolino et al. (2003b) | Libutti et al. (2003) | Biondi et al. (2004) | Loffler et al. (2007) | (This report) |
a
Cv, conventional; Cn, conditional.
b
PKG-Neo, phosphoglycerate kinase-neomycin; Neo-TK, neomycin-thymidine kinase; Rip-Cre, rat insulin promoter-causes recombination; Pth-Cre, parathyroid hormone-causes recombination.
c
129-129S6/SvEv; C57-C57BL/6.
d
↑Ca, hypercalcaemia; INS, insulin; GLU, glucagon; SSTR2, somatostatin receptor type 2; CgA, chromogranin A; PRL, prolactin; GH, growth hormone; NF, non-functioning; ACTH, adrenocorticotrophin; 3β-HSD, 3-beta-hydroxy steroid dehydrogenase; TH, tyrosine hydroxylase; NET, neuroendocrine tumours; LD, Leydig cell tumour; SC, sex cord stromal cell tumours; Cort, corticosterone.